p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer.
Détails
ID Serval
serval:BIB_8927F541FE8C
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer.
Périodique
Annals of Oncology
Collaborateur⸱rice⸱s
International Breast Cancer Study Group
Contributeur⸱rice⸱s
Goldhirsch A., Coates AS., Thürlimann B., Castiglione-Gertsch M., Hossfeld DK., Láng I., Lindtner J., Destoppani M., Rudenstam CM., Stahel R., Senn HJ., Veronesi A., Castiglione-Gertsch M., Coates AS., Collins JP., Cortés Funes H., Gelber RD., Goldhirsch A., Green M., Hiltbrunner A., Holmberg SB., Hossfeld DK., Láng I., Lindtner J., Destoppani M., Rudenstam CM., Stahel R., Senn HJ., Veronesi A., Castiglione-Gertsch M., Hiltbrunner A., Egli G., Rabaglio M., Maibach R., Studer R., Ruepp B., Marbot E., Kammler R., Pauli HR., Aeschbacher A., Oelhafen S., Gelber RD., Price KN., Regan MM., Gelber S., Cole B., Giobbie-Hurder A., Nickerson L., Blacher L., Hinkle R., Celano J., Viale G., Maiorano E., Mastropasqua M., Andrighetto S., Peruzzotti G., Ghisini R., Scarano E., Dell'Orto P., Del Curto B., Gusterson B., Mallon E., Pritchard K., Sutherland D., Sawka C., Taylor G., Choo G., Catzavelos C., Roche K., Wedad H., Láng I., Hitre E., Juhos E., Szamel I., Toth J., Orosz Z., Peter I., Crivellari D., Monfardini S., Galligioni E., Magri MD., Veronesi A., Buonadonna A., Massarut S., Rossi C., Candiani E., Carbone A., Perin T., Volpe R., Roncadin M., Arcicasa M., Coran F., Morassut S., Simoncini E., Marini G., Marpicati P., Braga M., Grigolato P., Lucini L., Foladore S., Foghin L., Pamich G., Bianchi C., Marino B., Murgia A., Milan V., Goldhirsch A., Colleoni M., Martinelli G., Orlando L., Nolé F., Luini A., Orecchia R., Viale G., Renne G., Mazzarol G., Peccatori F., de Braud F., Costa A., Zurrida S., Veronesi P., Sacchini V., Galimberti V., Intra M., Cinieri S., Peruzzotti G., Veronesi U., Ravaioli A., Tassinari D., Oliverio G., Barbanti F., Rinaldi P., Gianni L., Drudi G., Antimi M., Minelli M., Bellini V., Porzio R., Pernazza E., Santeusanio G., Spagnoli LG., Magazu M., Fosser V., Morandi P., Scalco G., Balli M., d'Amore ES., Meli S., Torsello G., Lindtner J., Erzen D., Majdic E., Stabuc B., Plesnicar A., Golouh R., Lamovec J., Jancar J., Vrhovec I., Kramberger M., Dent DM., Gudgeon A., Murray E., Langman G., Werner ID., Steynor P., Toop J., McEvoy E., Vorobiof D., Chasen M., Fotheringham G., de Muelenaere G., Skudowitz B., Mohammed C., Rosengarten A., Thatcher C., Cortés-Funes H., Mendiola C., Hornedo J., Colomer R., Cruz Vigo F., Miranda P., Sierra A., Martinez-Tello F., Garzon A., Alonso S., Ferrero A., Rudenstam CM., Suurküla M., Sjukhuset O., Havel G., Persson S., Svensson JH., Ostberg G., Holmberg SB., Wallgren A., Ottosson-Lönn S., Hultborn R., Colldahl-Jäderström G., Cahlin E., Mattsson J., Ivarsson L., Ruusvik O., Niklasson LG., Dahlin S., Karlsson G., Lindberg B., Sundbäck A., Bergegårdh S., Salander H., Andersson C., Heideman M., Hessman Y., Nelzén O., Claes G., Ramhult T., Kovacs A., Liedberg P., Fey MF., Castiglione-Gertsch M., Dreher E., Schneider H., Aebi S., Ludin J., Beck G., Haenel A., Lüthi JM., Mazzucchelli L., Musy JP., Altermatt HJ., Nandedkar M., Buser K., Senn HJ., Thürlimann B., Oehlschlegel Ch., Ries G., Töpfer M., Lorenz U., Schiltknecht O., Späti B., Ehrsam A., Bamert M., Jungi WF., Cavalli F., Pagani O., Neuenschwander H., Bronz L., Sessa C., Ghielmini M., Rusca T., Rey P., Bernier J., Pedrinis E., Gyr T., Leidi L., Pastorelli G., Caccia G., Goldhirsch A., Herrmann R., Rochlitz CF., Harder JF., Bartens S., Eppenberger U., Torhorst J., Moch H., Piguet D., Siegenthaler P., Barrelet V., Baumann RP., Christen B., Pestalozzi B., Sauter C., Fink D., Fehr M., Haller U., Metzger U., Huguenin P., Caduff R., Perey L., Leyvraz S., Anani P., Gomez F., Wellman D., Chapuis G., De Grandi P., Reymond P., Gillet M., Delaloye JF., Genton C., Fiche M., Alberto P., Bonnefoi H., Schäfer P., Krauer F., Forni M., Aapro M., Egeli R., Megevand R., Jacot-des-Combes E., Schindler A., Borisch B., Diebold S., Genta M., Pelte M., Egli F., Forrer P., Willi A., Steiner R., Allemann J., Rüedi T., Leutenegger A., Torre UD., Frick H., Collins J., Snyder R., Brown B., Abdi E., Armstrong H., Barling A., Basser R., Bhathal P., Burns WI., Chipman M., Chirgwin J., Davis I., Drummond R., Finkelde D., Francis P., Gee D., Goss G., Green M., Gregory P., Griffiths J., Hart S., Hastrich D., Henderson M., Holmes R., Jeal P., Joseph D., Kitchen P., Kostos P., Lindeman G., Mann B., McLennan R., Mileshkin L., Mitchell P., Murphy C., Neil S., Olver I., Pitcher M., Read A., Reading D., Reed R., Richardson G., Rodger A., Russell I., Schwarz M., Slade S., Stanley R., Steele M., Stewart J., Underhill C., Zalcberg J., Zimet A., Dow C., Valentine R., Malden T., Van Hazel G., Forbes JF., Braye S., Stewart J., Jackson D., Gourlay R., Bishop J., Cox S., Ackland S., Bonaventura A., Hamilton C., Denham J., O'Brien P., Back M., Brae S., Muragasu R., Friedlander M., Brigham B., Lewis C., Olver IN., Keefe D., Brown M., Gill PG., Taylor A., Yeoh E., Abdi E., Cleary J., Parnis F., Byrne M., Van Hazel G., Dewar J., Buck M., Sterrett G., Ingram D., Hastrich D., Joseph D., Cameron F., Shilkin KB., Michell P., Sharpio J., Harloe G., Lewis J., Snowball B., Webb PG., Harvey J., De Boer WD. , Robbins P., Buxton N., Walters MN., Beith J., Tattersall MH., Coates AS., Niesche F., West R., Renwick S., Donovan J., Duval P., Simes RJ., Ng A., Glenn D., North RA., O'Connor RG., Rice M., Stevens G., Grassby J., Pendlebury S., McLeod C., Boyer M., Sullivan A., Hobbs J., Lind D., Grace J., McKenzie P., Boadle D., Brain T., Byard I., Byram D., Harvey VJ., Kay RG., Thompson P., Porter D., Benjamin CS., Bierre A., Miller M., Hochstein B., Lethaby A., Webber J., Allen JP., Allon M., Arthur JF., Gurley M., Symmans P., Christie M., King AR., Kennedy I., Round G., Long J.
ISSN
1569-8041 (Electronic)
ISSN-L
0923-7534
Statut éditorial
Publié
Date de publication
2008
Volume
19
Numéro
4
Pages
660-668
Langue
anglais
Notes
Publication types: Comparative Study ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
BACKGROUND: Low p27 and high Skp2 immunoreactivity are associated with a poor prognosis and other poor prognostic features including resistant phenotypes and antiestrogen drug resistance. We investigated these proteins in two International Breast Cancer Study Group trials studying node-negative early breast cancer.
PATIENTS AND METHODS: Trial VIII compared chemotherapy followed by goserelin with either modality alone in premenopausal patients. Trial IX compared chemotherapy followed by tamoxifen with tamoxifen alone in postmenopausal patients. Central Pathology Office assessed p27 and Skp2 expression in the primary tumor by immunohistochemistry among 1631 (60%) trial patients.
RESULTS: p27 and Skp2 were inversely related; 13% of tumors expressed low p27 and high Skp2. Low p27 and high Skp2 were associated with unfavorable prognostic factors including larger size and higher grade tumors, absence of estrogen receptor and progesterone receptor, human epidermal growth factor receptor 2 overexpression and high Ki-67 (each P < 0.05). Low p27 and high Skp2 were not associated with disease-free survival (P = 0.42 and P = 0.48, respectively). The relative effects of chemo-endocrine versus endocrine therapy were similar regardless of p27 or Skp2.
CONCLUSIONS: We confirm the association of low p27 and high Skp2 with other poor prognostic features, but found no predictive or prognostic value, and therefore do not recommend routine determination of p27 and Skp2 for node-negative breast cancer.
PATIENTS AND METHODS: Trial VIII compared chemotherapy followed by goserelin with either modality alone in premenopausal patients. Trial IX compared chemotherapy followed by tamoxifen with tamoxifen alone in postmenopausal patients. Central Pathology Office assessed p27 and Skp2 expression in the primary tumor by immunohistochemistry among 1631 (60%) trial patients.
RESULTS: p27 and Skp2 were inversely related; 13% of tumors expressed low p27 and high Skp2. Low p27 and high Skp2 were associated with unfavorable prognostic factors including larger size and higher grade tumors, absence of estrogen receptor and progesterone receptor, human epidermal growth factor receptor 2 overexpression and high Ki-67 (each P < 0.05). Low p27 and high Skp2 were not associated with disease-free survival (P = 0.42 and P = 0.48, respectively). The relative effects of chemo-endocrine versus endocrine therapy were similar regardless of p27 or Skp2.
CONCLUSIONS: We confirm the association of low p27 and high Skp2 with other poor prognostic features, but found no predictive or prognostic value, and therefore do not recommend routine determination of p27 and Skp2 for node-negative breast cancer.
Mots-clé
Adult, Aged, Antineoplastic Agents, Hormonal/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Breast Neoplasms/chemistry, Breast Neoplasms/drug therapy, Cyclophosphamide/administration & dosage, Disease-Free Survival, Female, Fluorouracil/administration & dosage, Goserelin/administration & dosage, Humans, Immunohistochemistry, Methotrexate/administration & dosage, Middle Aged, Predictive Value of Tests, Prognosis, Proliferating Cell Nuclear Antigen/analysis, S-Phase Kinase-Associated Proteins/analysis, Tamoxifen/administration & dosage, Treatment Outcome, Tumor Markers, Biological/analysis
Pubmed
Web of science
Open Access
Oui
Création de la notice
05/03/2009 16:23
Dernière modification de la notice
20/08/2019 15:48
Données d'usage
